A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

Part of paid clinical trials in Duarte, California.

Sponsor
Tempus AI
Study ID
NCT06163534
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.

Key Dates

Start date
Aug 1, 2024
Status verified
Mar 2026
Primary completion
Mar 1, 2028
Completion
Mar 1, 2028

Study Design

Enrollment
500 participants (estimated)

Arms

  • Arm: Metastatic or unresectable recurrent HNSCC
    Up to 500 participants (including primary tumor location of pharynx, larynx, oral cavity and oropharynx) with metastatic or unresectable recurrent HNSCC who are intended for first line immunotherapy or combination therapy. No intervention.

Primary Outcome Measure

Explore DNA, RNA, immune and other multiomic biomarkers to better understand prognostic or predictive biomarkers and to inform future research for new relevant biomarkers. [ Time Frame: 5 years ]

Central Contacts

Locations (29)

FacilityCityStateZIPSite coordinators
City of HopeDuarteCalifornia91010
Angelica Hamilton
[email protected]
626-218-0109
Ravi Salgia (PRINCIPAL_INVESTIGATOR)
University of California, Los AngelesLos AngelesCalifornia90095
Youstina Zaki
[email protected]
310-794-4955
Deborah Wong (PRINCIPAL_INVESTIGATOR)
USC/Norris Comprehensive Cancer CenterLos AngelesCalifornia90033
Jacob Thomas (PRINCIPAL_INVESTIGATOR)
StanfordPalo AltoCalifornia94304
Savanna Biedermann
[email protected]
650-497-7418
Saad Khan (PRINCIPAL_INVESTIGATOR)
Providence Medical FoundationSanta RosaCalifornia95403
Davina Montelongo
[email protected]
707-521-3830
Ian Anderson (PRINCIPAL_INVESTIGATOR)
MorehouseAtlantaGeorgia30310
Jessica Williams
[email protected]
404-789-3826
Roland Matthews (PRINCIPAL_INVESTIGATOR)
Piedmont HealthcareAtlantaGeorgia30318
Jeff Whorton
[email protected]
770-630-9299
Sope Olugbile (PRINCIPAL_INVESTIGATOR)
Winship Cancer Institute, Emory UniversityAtlantaGeorgia30322
Cecilia Gamra
[email protected]
404-686-1638
Nabil Saba, MD (PRINCIPAL_INVESTIGATOR)
Northwestern University Feinberg School of MedicineChicagoIllinois60611
Genesis Chase
[email protected]
312-695-1519
Jochen Lorch (PRINCIPAL_INVESTIGATOR)
Cancer Care Specialists of IllinoisDecaturIllinois62526
Kaitlynn Kapp
[email protected]
618-589-9721
James Wade (PRINCIPAL_INVESTIGATOR)
Illinois Cancer CarePeoriaIllinois61615
Emilie Nkangu
[email protected]
309-243-3663
Fahad Asad (PRINCIPAL_INVESTIGATOR)
University of KansasWestwoodKansas66205
Emmanuel Mado
[email protected]
913-945-9429
Prakash Neupane (PRINCIPAL_INVESTIGATOR)
University of MarylandBaltimoreMaryland21202
Rehan Khan
[email protected]
410-328-7496
Ranee Mehra (PRINCIPAL_INVESTIGATOR)
Dana Farber Cancer InstituteBostonMassachusetts02215
Sage Yenari
[email protected]
617-632-8039
Robert Haddad (PRINCIPAL_INVESTIGATOR)
Henry FordDetriotMichigan48202
Molly Constantino
[email protected]
Matthew Wilkins (PRINCIPAL_INVESTIGATOR)
Karmanos Cancer InstituteDetroitMichigan48201
Walid Sukari
[email protected]
Ammar Sukari, MD (PRINCIPAL_INVESTIGATOR)
Oncology Hematology AssociatesSpringfieldMissouri65807
Adrianna Moore
[email protected]
417-882-4880
V. Roger Holden, MD, PHD (PRINCIPAL_INVESTIGATOR)
Washington University in St. LouisSt LouisMissouri63130
Samuel Williams
[email protected]
314-747-2626
Douglas Adkins, MD (PRINCIPAL_INVESTIGATOR)
Mount Sinai HospitalNew YorkNew York10029
Julia Miller
[email protected]
212-824-5378
Kryzsztof Misiukiewicz (PRINCIPAL_INVESTIGATOR)
Sanford FargoFargoNorth Dakota58102
Signe Harris
[email protected]
701-234-7515
Daniel Almquist (PRINCIPAL_INVESTIGATOR)
University of CincinnatiCincinnatiOhio45219
Shelby Mitchell
[email protected]
513-584-6195
Chris Lemmon, MD (PRINCIPAL_INVESTIGATOR)
Cleveland ClinicClevelandOhio44195
Alfred Kotarja
[email protected]
216-442-1947
Shlomo Koyfman (PRINCIPAL_INVESTIGATOR)
Ohio State UniversityColumbusOhio43210
Harley Hamilton
[email protected]
614-293-6522
Marcelo Bonomi (PRINCIPAL_INVESTIGATOR)
University of PennsylvaniaPhiladelphiaPennsylvania19104
Daniel Huth
[email protected]
541-778-0331
Lova Sun (PRINCIPAL_INVESTIGATOR)
Cancer Care Associates of YorkYorkPennsylvania17403
Clarissa Vega
[email protected]
Chanh Huynh (PRINCIPAL_INVESTIGATOR)
Sanford Sioux FallsSioux FallsSouth Dakota57104
Brenna Many Horses
[email protected]
605-312-6217
Steven Powell (PRINCIPAL_INVESTIGATOR)
Vanderbilt UniversityNashvilleTennessee37212
Ilyana Ilieva
[email protected]
615-936-0960
Jennifer Choe (PRINCIPAL_INVESTIGATOR)
University of WashingtonSeattleWashington98109
Marcus Schoenfeld
[email protected]
206-606-7487
Cristinia Rodriguez (PRINCIPAL_INVESTIGATOR)
ThedaCareAppletonWisconsin54911
Sarah Loether
[email protected]
920-364-3604
Matthias Weiss (PRINCIPAL_INVESTIGATOR)

Find similar trials in Duarte, CA

By condition
Head and neck cancer
By specialty
OncologyENT
By research site
City of Hope· Duarte, CAUniversity of California, Los Angeles· Los Angeles, CAUSC/Norris Comprehensive Cancer Center· Los Angeles, CAStanford· Palo Alto, CAProvidence Medical Foundation· Santa Rosa, CAMorehouse· Atlanta, GA

Related Studies